Dr. Reddy’s Clarifies US FDA Tentative Approval for Generic HIV Drug Lenacapavir
Dr Reddys Laboratories Ltd · Others (Uncategorized) · 04 Nov 2026, 5:15 pm
Dr. Reddy’s Clarifies US FDA Tentative Approval for Generic HIV Drug Lenacapavir Dr. Reddy’s Laboratories confirmed media reports regarding US FDA tentative approval for its twice-yearly injectable lenacapavir, aimed at expanding generic HIV prevention access across 120 countries outside the US. Responding to a BSE clarification request dated 3rd Nov'26, the company stated the news relates to its 2nd Nov'26 press release. Dr. Reddy’s highlighted that the development does not constitute a material event or require disclosure under Regulation 30 of SEBI Listing Regulations, maintaining adherence to all mandatory disclosure compliance requirements.
Original exchange filing (PDF)
More announcements from Dr Reddys Laboratories Ltd
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 14 Nov 2026
- Intimation of Analyst meet · 11 Nov 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 05 Nov 2026
- Allotment of Employee Stock options · 04 Nov 2026
- The Exchange has sought Clarification from Dr Reddys Laboratories Ltd with reference to the media report appearing on https://www.firstpost.com dated November 03, 2026 (Link : https://www.firstpost.com/business/indias-dr-reddys-gets-us-nod-for-40-generic-hiv-prevention-shot-for-120-poorer-countries-14057224.html) .... · 03 Nov 2026
- Transcript of Earnings call · 30 Oct 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 28 Oct 2026
- Audio Recording of the Earnings call conducted on October 23, 2026 · 24 Oct 2026
